A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

[1]  Syed Abbas Ali,et al.  T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. , 2016, Blood.

[2]  N. Munshi,et al.  APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. , 2016, Blood.

[3]  Michael L. Wang,et al.  Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor , 2015 .

[4]  João Moura,et al.  Chemokine Receptor Expression on Normal Blood CD56+ NK-Cells Elucidates Cell Partners That Comigrate during the Innate and Adaptive Immune Responses and Identifies a Transitional NK-Cell Population , 2015, Journal of immunology research.

[5]  K. Anderson,et al.  Targeting B-cell maturation antigen in multiple myeloma. , 2015, Immunotherapy.

[6]  Jessica Katz,et al.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. , 2015, The New England journal of medicine.

[7]  P. Sonneveld,et al.  Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma , 2015, Expert review of hematology.

[8]  Yunxin Chen,et al.  Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development , 2015, Therapeutic advances in hematology.

[9]  M. Sanford.  Blinatumomab: First Global Approval , 2015, Drugs.

[10]  N. Munshi,et al.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. , 2014, Blood.

[11]  A. Henn,et al.  Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia , 2014, Molecular Cancer Therapeutics.

[12]  K. Yong,et al.  Evaluation Of Bcma As a Therapeutic Target In Multiple Myeloma Using An Antibody-Drug Conjugate , 2013 .

[13]  M. Raffeld,et al.  B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma , 2013, Clinical Cancer Research.

[14]  M. Friedrich,et al.  Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens , 2012, Molecular Cancer Therapeutics.

[15]  J. Crowley,et al.  Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival , 2012, British journal of haematology.

[16]  T. Marafioti,et al.  APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. , 2011, Blood.

[17]  KyungMann Kim,et al.  Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells , 2010, Molecular Cancer.

[18]  R. Noelle,et al.  The immortality of humoral immunity , 2010, Immunological reviews.

[19]  N. Munshi,et al.  Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. , 2009, Cancer cell.

[20]  P. Kufer,et al.  BiTE: Teaching antibodies to engage T-cells for cancer therapy. , 2009, Current opinion in molecular therapeutics.

[21]  P. Kufer,et al.  The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct , 2007, Cancer Immunology, Immunotherapy.

[22]  R. Kimmig,et al.  MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. , 2006, Molecular immunology.

[23]  Y. Natkunam,et al.  Utility of Syndecan-1 (CD138) Expression in the Diagnosis of Undifferentiated Malignant Neoplasms: A Tissue Microarray Study of 1,754 Cases , 2005, Applied immunohistochemistry & molecular morphology : AIMM.

[24]  P. Hoffmann,et al.  Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct , 2005, International journal of cancer.

[25]  K. Tarte,et al.  BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone , 2003 .

[26]  R. Bargou,et al.  T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent , 2004, Cancer Immunology, Immunotherapy.

[27]  B. Harder,et al.  Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. , 2004, Blood.

[28]  R. Bram,et al.  BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells , 2004, The Journal of experimental medicine.

[29]  K. Lam,et al.  B-Cell Maturation Protein, Which Binds the Tumor Necrosis Factor Family Members BAFF and APRIL, Is Dispensable for Humoral Immune Responses , 2001, Molecular and Cellular Biology.

[30]  A. P. Bolliger,et al.  Cytological examination and cellular composition of bone marrow in healthy, adult, cynomolgus monkeys (Macaca fascicularis) , 1998, Comparative Haematology International.

[31]  M. Dimopoulos,et al.  Current treatment landscape for relapsed and/or refractory multiple myeloma , 2015, Nature Reviews Clinical Oncology.